Arno Therapeutics(OTC) ARNI

Arno Therapeutics, Inc. is a biopharmaceutical company based in Flemington, New Jersey, dedicated to developing innovative treatments for cancer and other serious health conditions. The company is advancing several promising compounds through clinical trials, focusing on addressing unmet medical needs in oncology.

Products and Services

• Onapristone: A type 1 anti-progestin hormone blocker in Phase I/II trials for solid tumors
• AR-12: An oral cancer therapy that has completed Phase I studies for various malignancies
• AR-42: An oral treatment targeting hematological malignancies and solid tumors, currently in Phase I studies

Growth Outlook

• Onapristone shows potential for treating advanced prostate and breast cancers
• AR-12 is in pre-clinical development for microbial targets, expanding its application
• Collaborations with universities and pharmaceutical companies enhance research capabilities

Financial Highlights

• Recent quarterly net income of -$3.85 million reflects ongoing R&D investments
• Cash and cash equivalents increased to $2.12 million in Q3 2016
• Operating cash flow remains negative, indicating a focus on development over immediate profitability

Arno Therapeutics, Inc. is positioned in the biotechnology sector, focusing on innovative cancer therapies. The company's lead product, Onapristone, is currently undergoing clinical trials, which could significantly impact its market position if successful. The ongoing development of AR-12 and AR-42 further diversifies the product pipeline, potentially leading to multiple revenue streams in the future. The financial landscape shows a commitment to research and development, with substantial investments reflected in the recent quarterly losses. However, the increase in cash reserves indicates a strategic approach to funding ongoing projects. Collaborations with academic institutions and other pharmaceutical companies may enhance the company's research capabilities and accelerate the development of its therapeutic candidates. Overall, Arno Therapeutics, Inc. presents a compelling opportunity for investors interested in the biotechnology sector, particularly in the area of cancer treatment. The company's innovative approach and strategic partnerships may position it for future growth and success in a competitive market.